1483 related articles for article (PubMed ID: 15884724)
1. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
5. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
6. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
7. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
[TBL] [Abstract][Full Text] [Related]
8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
9. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
10. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
12. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
[No Abstract] [Full Text] [Related]
13. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
[TBL] [Abstract][Full Text] [Related]
14. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
15. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
[No Abstract] [Full Text] [Related]
16. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
[TBL] [Abstract][Full Text] [Related]
17. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Kageyama S
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
[No Abstract] [Full Text] [Related]
18. [CHARM study--new strategy for the treatment of heart failure].
Hasegawa H; Komuro I
Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
20. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]